Silverarc Capital Management LLC Raises Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Silverarc Capital Management LLC increased its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 52.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 734,234 shares of the company's stock after buying an additional 251,659 shares during the quarter. Silverarc Capital Management LLC owned 0.96% of Trevi Therapeutics worth $3,025,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Summit Investment Advisors Inc. increased its position in shares of Trevi Therapeutics by 84.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock valued at $26,000 after acquiring an additional 2,894 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Trevi Therapeutics in the fourth quarter worth about $49,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Trevi Therapeutics in the fourth quarter worth about $67,000. Jump Financial LLC purchased a new position in Trevi Therapeutics during the 4th quarter valued at about $89,000. Finally, Invesco Ltd. raised its position in Trevi Therapeutics by 21.2% during the 4th quarter. Invesco Ltd. now owns 23,621 shares of the company's stock valued at $97,000 after purchasing an additional 4,133 shares during the last quarter. 95.76% of the stock is currently owned by institutional investors.

Insider Transactions at Trevi Therapeutics

In other news, CEO Jennifer L. Good sold 5,263 shares of the stock in a transaction that occurred on Friday, March 21st. The shares were sold at an average price of $6.58, for a total transaction of $34,630.54. Following the sale, the chief executive officer now owns 213,313 shares in the company, valued at $1,403,599.54. This represents a 2.41 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Farrell Simon sold 81,313 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the sale, the insider now directly owns 76,900 shares of the company's stock, valued at $519,075. This trade represents a 51.39 % decrease in their position. The disclosure for this sale can be found here. Insiders own 24.37% of the company's stock.

Trevi Therapeutics Trading Up 1.9 %

TRVI traded up $0.12 during midday trading on Friday, reaching $6.47. The company's stock had a trading volume of 1,149,945 shares, compared to its average volume of 1,110,844. Trevi Therapeutics, Inc. has a 1 year low of $2.30 and a 1 year high of $7.39. The stock's 50-day moving average is $5.67 and its 200-day moving average is $4.25. The firm has a market capitalization of $625.53 million, a price-to-earnings ratio of -14.70 and a beta of 0.41.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01. As a group, equities research analysts forecast that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

TRVI has been the topic of a number of recent analyst reports. Oppenheimer lifted their price objective on Trevi Therapeutics from $12.00 to $20.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and set a $12.50 price objective on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Raymond James raised shares of Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and raised their target price for the stock from $9.00 to $29.00 in a research report on Monday, March 10th. D. Boral Capital reissued a "buy" rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Finally, B. Riley reaffirmed a "buy" rating and set a $20.00 price objective (up from $11.00) on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Seven analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, Trevi Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $17.56.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.